Himalaya Nutravedics India Limited, a Hyderabad-based manufacturer of Ayurvedic and nutraceutical formulations, has filed its Draft Red Herring Prospectus for an SME IPO. The company, operational since September 2022, plans to open its issue on September 22, 2026, and close it on September 24, 2026, with listing expected on September 29, 2026.

About the Company

Himalaya Nutravedics manufactures classical Ayurvedic formulations, proprietary Ayurvedic products, and nutraceutical supplements. It operates through a hybrid model that includes own-brand products and third-party contract manufacturing. The company’s integrated facility in Cherlapally, Hyderabad, is certified under WHO-GMP, ISO 9001:2015, and ISO 22000:2018. It produces softgel capsules, tablets, medicated oils, liquid orals, and hardgel capsules.

The business follows a doctor-centric, offline distribution model supported by approximately 58 sales personnel. Its portfolio spans over 100 products across therapeutic categories such as gut health, cardiac wellness, diabetes management, pain management, immunity, and infertility. In FY2026, Ayurvedic products accounted for 94.57% of revenue from operations, while the branded business constituted 51.14% of total revenues. The company distributes its products across 17 states.

Financial Performance

The company has demonstrated significant top-line and bottom-line growth over the last three fiscal years. Revenue from operations surged from ₹14.43 crore in FY2024 to ₹43.07 crore in FY2026. Profit after tax (PAT) grew from ₹0.43 crore in FY2024 to ₹7.39 crore in FY2026. PAT margins expanded from 2.98% in FY2024 to 17.14% in FY2026, aided by operating leverage and a Section 80-IAC tax holiday benefit that continues through FY2027.

Despite profitability, the company reported negative operating cash flows in all three years: -₹0.55 crore in FY2024, -₹1.39 crore in FY2025, and -₹3.83 crore in FY2026. This was driven by elevated working capital requirements, including high inventory levels and rising trade receivables. Total assets grew from ₹6.09 crore in FY2024 to ₹24.42 crore in FY2026, while debt-to-equity ratio improved from 3.49x to 0.49x.

Why the Company Is Raising Funds

The company intends to deploy net proceeds towards specific strategic initiatives. The disclosed use of proceeds totals a minimum of ₹21.25 crore, with the balance allocated for general corporate purposes subject to regulatory limits.

• Working Capital: ₹13.75 crore to fund working capital requirements, support inventory levels, and accelerate expansion into Direct-to-Consumer (D2C) segments.
• Branding & Marketing: ₹7.50 crore for branding, digital marketing, sales expansion, advertising on e-commerce platforms, and developing a proprietary D2C website.
• General Corporate Purposes: Remaining proceeds for strategic initiatives, strengthening marketing networks, and ordinary course of business expenses.

Business Strengths

• Integrated Manufacturing: Capability to produce multiple dosage forms including softgels, tablets, and oils under one roof, ensuring quality control and faster time-to-market.
• Doctor-Centric Model: Achieves repeat prescriptions through scientific detailing and medical camps rather than mass advertising, keeping marketing expenses at 4.16% of total revenue in FY2026.
• Geographic Expansion: Established presence across 17 states within approximately three years of commencing operations.
• Broad Portfolio: Offers products across diverse therapeutic categories, reducing dependence on any single segment.

Key Risks

• Negative Operating Cash Flows: The company has sustained negative cash flows from operations for three consecutive years, relying on financing activities to sustain operations.
• Customer Concentration: Top 10 customers contributed 81.24% of revenue in FY2026. There are no long-term contractual arrangements with these customers.
• Tax Holiday Expiry: The Section 80-IAC tax benefit expires post-FY2027. Upon expiry, PAT is estimated to reduce by approximately 28% of the corresponding profit before tax.
• Single Facility Risk: Operations depend on a single leased manufacturing facility in Hyderabad, exposing the company to geographical concentration risks.
• Supplier Concentration: Top 10 suppliers account for 94.30% of total purchases in FY2026, with no long-term supply agreements in place.
• Trademark Opposition: Pending opposition proceedings against two trademark applications could impact brand recognition if resolved adversely.

Important IPO Dates

• IPO Opening Date: 22-Sep-2026
• IPO Closing Date: 24-Sep-2026
• Allotment Date: 25-Sep-2026
• Listing Date: 29-Sep-2026

Offer Details

The offer consists entirely of a fresh issue. There is no offer for sale component. Specific details regarding the price band, lot size, and total issue size are not disclosed in the current filing data. Reservation categories will follow standard SME IPO norms.

Bottom Line

Himalaya Nutravedics India presents a high-growth profile with revenue tripling to ₹43.07 crore in FY2026 and expanding margins. However, investors must weigh this growth against persistent negative operating cash flows, high customer concentration, and the impending expiry of tax benefits. The IPO proceeds are primarily aimed at strengthening working capital and accelerating digital marketing efforts to sustain this trajectory.